<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775242</url>
  </required_header>
  <id_info>
    <org_study_id>02/PAF/06</org_study_id>
    <secondary_id>0607/I/APL</secondary_id>
    <nct_id>NCT00775242</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.</brief_title>
  <official_title>Comparative Efficacy and Safety Study of Three Different Doses of a Formulation Composed of Crystalline Estradiol and Progesterone Microspheres, Indicated for Monthly IM Injection for the Treatment ot Climacteric Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro A.F. de Estudios Tecnologicos, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro A.F. de Estudios Tecnologicos, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During menopause a woman's body slowly produces less of the hormones estrogen and
      progesterone. Lower hormone levels in menopause may lead to hot flashes, vaginal dryness and
      osteoporosis. To help with these problems, women are often given estrogen or estrogen with
      progestin. The purpose of this study is to assess and compare the efficacy and safety of
      three doses of estradiol and progesterone for the treatment of the climacteric symptoms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different formulations of estrogens and progestins have been used for the treatment of
      climacteric symptoms, however up to this date no formulation is completely satisfactory. Our
      company has developed a new technology for the preparation of controlled release bioerodible
      non-polymeric microspheres, these microspheres are capable of delivering doses of estradiol
      (E) and progesterone (P) at levels appropriate for the Hormonal Replacement Therapy (HRT) in
      order to relieve the climacteric symptoms. Non clinical and clinical studies have been
      conducted aimed at assessing the pharmacokinetics of these microspheres, at several doses of
      progesterone and estradiol. Results show that sustained plasma profiles for both steroids
      within the therapeutic range for several days are attained. On this basis, a new efficacy and
      safety study is going to be conducted with the purpose of assessing and defining the most
      appropriate doses of estradiol and progesterone for the HRT of the climacteric symptoms.

      Three different doses of progesterone and estradiol (0.5 mg of E + 15 mg of P vs 1 mg of E +
      20 mg of P vs 1 mg of E + 30 mg of P) will be compared in terms of their efficacy and safety
      to treat the climacteric symptoms in healthy postmenopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of frequency and intensity of vasomotor symptoms</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6 and 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and intensity of vulvar and vaginal atrophy symptoms Vaginal pH Index of vaginal maturation (surface, intermediate and parabasal cells) Karyopiknotic index Lipids profile Utian quality of life scale Green climacteric symptoms scale</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6 and 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Estradiol and progesterone injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol and Progesterone</intervention_name>
    <description>Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.</description>
    <arm_group_label>Estradiol and progesterone injection</arm_group_label>
    <other_name>estrogens and progestines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol and Progesterone</intervention_name>
    <description>Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period</description>
    <arm_group_label>Estradiol and progesterone injection</arm_group_label>
    <other_name>Estrogens</other_name>
    <other_name>Progestins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 40 and 65 years.

          -  Perimenopausal subjects: Women showing spontaneous amenorrhea during the last 11
             months.

          -  Postmenopausal subjects: Women with not less than 12 consecutive months of amenorrhea
             and FSH &gt; 40 mIU/mL

          -  Subjects showing vasomotor symptoms, not less than 3 hot flashes in a day or not less
             than 21 hot flashes in a week

          -  Healthy subjects determined on the basis of a satisfactory complete clinical history,
             clinical laboratory tests, cervical cytology, endometrium biopsy and vaginal pelvic
             ultrasonography.

          -  Subjects not receiving any hormonal treatment.

        Exclusion Criteria:

          -  Subjects with background of endometrial hyperplasia or endometrial cancer.

          -  Subjects with endometrial hyperplasia or endometrial cancer assessed by endometrial
             biopsy.

          -  Perimenopausal subjects with background of abnormal uterine bleeding unless the
             Principal Clinical Investigator considers that this abnormality is secondary to the
             menopausal condition.

          -  Subjects with hypersensitivity to any medicament.

          -  Subjects with direct family background of breast cancer.

          -  Subjects with background of cardiovascular disease, renal, hepatic, metabolic,
             gastrointestinal, neurologic, endocrine, gynecologic disease including dysfunctional
             uterine bleeding, cervico uterine dysplasia, cancer, anemia, emotional disorders, or
             any other chronic degenerative disorders which could affect her participation in the
             study.

          -  Subjects who require any medicament in the course of the study unless the Principal
             Clinical Investigator considers that there is no pharmacological interaction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Cortes Bonilla, Ob/Gyn</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Centro A.F. de Estudios Tecnologicos, S.A.</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>August 21, 2009</last_update_submitted>
  <last_update_submitted_qc>August 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Juan Angeles Uribe</name_title>
    <organization>Centro A.F. de Estudios Tecnol√≥gicos, S.A.</organization>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Hormone Replacement Therapy</keyword>
  <keyword>Microspheres</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Hot flashes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

